Preclinical screening for antidepressant activity - shifting focus away from the Forced Swim Test to the use of translational biomarkers.
Regul Toxicol Pharmacol
; 125: 105002, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-34245825
ABSTRACT
Depression is the world's predominant mental health problem and a leading cause of disability. Neuropharmacological research has not yet advanced treatments to sufficiently meet clinical need, largely due to the failure of animal models to predict clinical efficacy. The forced swim test (FST) has been extensively used in the field of antidepressant research but has been under scrutiny due to its perceived severity to animals. Any use of animals in experiments and testing must have a scientific or regulatory purpose and researchers need to ensure that there is no scientifically valid alternative. However, regulatory requirements have been incorrectly cited as a reason to support the use of the FST. More research is required on tests that do not involve stressing animals as replacements for the FST. Non-behavioural neurochemical measures might provide a means to advance neuropharmacological developments while reducing animal suffering. For example, brain-derived neurotrophic factor (BDNF) may be promising.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Factor Neurotrófico Derivado del Encéfalo
/
Alternativas al Uso de Animales
/
Antidepresivos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Animals
País/Región como asunto:
Europa
Idioma:
En
Revista:
Regul Toxicol Pharmacol
Año:
2021
Tipo del documento:
Article